VIPR2 mFc Chimera, Human
VIPR2 MFc Chimera, Human

The purity of VIPR2 mFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

VIPR2 MFc Chimera, Human

VIPR2 mFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

VIPR2 mFc Chimera, Human

Effects of vasoactive intestinal peptide (VIP) on T cell migration are mediated by structurally distinct types I (VIPR1) and II (VIPR2) G protein-associated receptors. The two receptor types were proposed to transduce opposite effects on human T cells, since cytokine-induced chemotaxis of VIPR1-bearing HuT 78 human T cells, in contrast to T cells that express VIPR2, was inhibited by VIP.
Z05956
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
VIPR2 (Glu24-Val126)_x000D_
Accession # P41587-1		 mFc (IgG1)
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 37.35 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 45-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • VIPR2 MFc Chimera, Human
    • VIPR2 MFc Chimera, Human

    The purity of VIPR2 mFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • VIPR2 MFc Chimera, Human
    • VIPR2 MFc Chimera, Human

    VIPR2 mFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Effects of vasoactive intestinal peptide (VIP) on T cell migration are mediated by structurally distinct types I (VIPR1) and II (VIPR2) G protein-associated receptors. The two receptor types were proposed to transduce opposite effects on human T cells, since cytokine-induced chemotaxis of VIPR1-bearing HuT 78 human T cells, in contrast to T cells that express VIPR2, was inhibited by VIP.
Synonyms VIP-R-2; VPAC2; PACAP-R-3; PACAP-R3; VIPR2; VIP2R

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.